(Editor's Note: This article, which was originally published on July 11, 2002, incorrectly stated that the short-term ratings were remaining on CreditWatch. The short-term ratings were affirmed and are not on Credit Watch. A corrected version follows.) NEW YORK (Standard&Poor's) July 12, 2002—Standard&Poor's said today that its triple-'A' corporate credit and long-term debt ratings on pharmaceutical company Bristol-Myers Squibb Co. remain on CreditWatch, with negative implications, pending a review of the company's earnings growth prospects over the next several years. This announcement follows Bristol-Myers Squibb's confirmation that it has been in discussions since April 2002 with the Securities and Exchange Commission (SEC) concerning its sales incentive practices. At the same time, Standard and Poor's affirmed its
